Fujii Hayahiko, Nakadate Masashi, Tanaka Hiroaki, Harata Naoki, Oota Sayako, Isogai Jun, Yoshida Katsuya
Department of Radiology, Asahi General Hospital, 1326 I, Asahi, Chiba, 289-2511, Japan.
Department of Diagnostic Radiology, Medical Hospital, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Ann Nucl Med. 2016 Dec;30(10):756-759. doi: 10.1007/s12149-016-1122-7. Epub 2016 Sep 10.
To assess F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) images in primary thyroid lymphoma (PTL) patients before and after treatment.
We conducted a retrospective review of data for ten patients (four men, six women) of mean age 65 (range 48-88) years, with histopathologically confirmed malignant thyroid lymphoma who underwent pre-treatment and post-treatment F-FDG PET between January 2005 and December 2014. Thyroid uptake was assessed by the 5-point scale score based on maximum intensity projection images.
Four of the ten patients were judged to have a complete metabolic response (scores 1-3) and four to have a partial metabolic response (PMR; scores 4-5). Three of the four PMR patients had a good outcome with a treatment-free interval and overall survival of at least 53.0 months, although two of these three patients showed residual FDG uptake in the thyroid for more than 2 years after completion of treatment. Two of the ten patients were considered to have progressive metabolic disease.
In patients with PTL, residual FDG uptake in the thyroid after treatment that corresponds to a PMR may not always indicate a poor outcome.
评估原发性甲状腺淋巴瘤（PTL）患者治疗前后的氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（F-FDG PET/CT）图像。
我们对2005年1月至2014年12月期间10例（4例男性，6例女性）平均年龄65岁（范围48-88岁）、经组织病理学确诊为恶性甲状腺淋巴瘤且接受了治疗前和治疗后F-FDG PET检查的患者的数据进行了回顾性分析。基于最大强度投影图像，采用5分制评分评估甲状腺摄取情况。
10例患者中有4例被判定为完全代谢缓解（评分1-3分），4例为部分代谢缓解（PMR；评分4-5分）。4例PMR患者中有3例预后良好，无治疗间期和总生存期至少为53.0个月，尽管这3例患者中有2例在治疗完成后2年多甲状腺仍有残留FDG摄取。10例患者中有2例被认为有进行性代谢疾病。
在PTL患者中，治疗后甲状腺残留FDG摄取对应PMR时，并不总是提示预后不良。
